Research Appraisalobservational

Decoding the renal-cochlear axis: explainable machine learning and phenotype clustering reveal high-risk hearing loss subtypes in CKD

Renal failureChen, Ling, Wang, Jing, Liu, Guiqun et al.1 Dec 2026DOI

Clinical Snapshot

65CEBM
Evidence: Moderateobservational

PICO Framework

P — Population3,402 patients with chronic kidney disease from NHANES database
I — InterventionMachine learning-based risk stratification and phenotype clustering
C — ComparatorLow-risk versus high-risk hearing loss subtypes
O — OutcomesHearing loss prevalence, risk prediction accuracy (AUC), and phenotype classification

Bottom Line

This cross-sectional study of 3,402 CKD patients from NHANES developed a machine learning framework identifying two distinct hearing loss risk phenotypes, with high-risk patients showing 48.2% versus 1.58% hearing loss prevalence. While the XGBoost model demonstrated high discrimination (AUC 0.939), the extremely high training AUC values (0.984) raise overfitting concerns. The study provides proof-of-concept for ML-based risk stratification in CKD-associated hearing loss, identifying age as the predominant risk factor. However, the cross-sectional design prevents causal inference, and key methodological details regarding CKD and hearing loss definitions are lacking. External validation in independent cohorts is essential before clinical implementation. The findings support integrating hearing assessments into routine CKD care but require local validation and clearer diagnostic criteria for Australian practice.

Evidence: Moderate

Key Findings

  • P Value: Not reported

  • Effect Size: 48.2% vs 1.58% hearing loss prevalence (high-risk vs low-risk subtypes)

  • Primary Outcome: Hearing loss prevalence stratified by risk subtypes

  • Nnt Or Sensitivity: AUC 0.939 (testing set), 0.984 (training/validation)

  • Confidence Interval: Not reported

Clinical Application

Web-based tool developed but requires validation; integration into routine CKD care would need workflow adaptation Relevant to Australian CKD management but requires local validation; could inform RACGP chronic disease management and specialist referral pathways CKD patients requiring hearing loss risk assessment, particularly in nephrology and audiology settings

Abstract

This study develops a dual-level machine learning framework for risk stratification and phenotyping of hearing loss (HL) in patients with chronic kidney disease (CKD) using data from the National Health and Nutrition Examination Survey (NHANES). From a cohort of 3,402 CKD patients, feature selection via univariate and multivariate logistic regression identified key predictors, which were used to construct predictive models with nine machine learning algorithms. The eXtreme Gradient Boosting (XGBoost) model demonstrated superior performance, with mean area under the curve (AUC) values of 0.984 (training), 0.984 (validation), and 0.939 (testing). SHapley Additive exPlanations (SHAP) interpretation identified age as the predominant risk determinant. Subsequent Gaussian mixture modeling (GMM) clustered patients into two distinct subtypes: a low-risk subgroup (n = 1,075) with a 1.58% HL prevalence and a high-risk subgroup (n = 2,316) characterized by older age, elevated blood urea nitrogen and bicarbonate levels, and a 48.2% HL prevalence. A classifier trained on these subtypes achieved discrimination (AUC = 0.99974). A clinically a web-based tool was also developed based on the six most influential features. The findings establish a dual-level predictive framework integrating explainable ML and unsupervised clustering for HL risk assessment in CKD. This approach provides a robust strategy for the precision screening of high-risk subpopulations and supports the integration of hearing assessments into routine CKD.

References

  1. 1.Chen, L., Wang, J., Liu, G., Zhao, Y., Zhou, Z., & Li, Q. (2026). Decoding the renal-cochlear axis: explainable machine learning and phenotype clustering reveal high-risk hearing loss subtypes in CKD. Renal Failure. https://doi.org/10.1080/0886022X.2026.2649658
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service